Source comparison
Tesamorelin + Ipamorelin Blend: Research Application Comparison
Visceral adiposity reduction in lipodystrophy 15.2% VAT reduction over 26 weeks (COSMIX trial) Limited specific VAT data; 3.6% total body fat reduction in 16 weeks Theoretical 18–22% VAT reduction based on additive GH response (extrapolated) Tesamorelin monoth
This comparison does not assign a generated winner or score.
- Visceral adiposity reduction in lipodystrophy
- 15.2% VAT reduction over 26 weeks (COSMIX trial)
- Limited specific VAT data; 3.6% total body fat reduction in 16 weeks
- Theoretical 18–22% VAT reduction based on additive GH response (extrapolated)
- Tesamorelin monotherapy has strongest evidence base for pathological VAT; blend justified when response plateaus
- Age-related sarcopenic obesity
- 1.1kg lean mass gain + fat loss (HIV studies; non-elderly cohort)
- 2.8% lean mass increase in GH-deficient adults; preserves muscle during deficit
- Potential for simultaneous fat loss + muscle preservation via dual anabolic pathways
- Blend addresses both components of sarcopenic obesity; ipamorelin's selective GHS-R1a binding avoids cortisol-driven catabolism
- Insulin sensitivity improvement
- Fasting insulin improved 8–12% in tesamorelin trials (secondary endpoint)
- Minimal direct insulin data; GH elevation theoretically opposes insulin sensitivity acutely
- Mixed effects: acute GH opposes insulin action; chronic IGF-1 elevation improves sensitivity
- Use cautiously in insulin-resistant populations; monitor HbA1c and fasting glucose closely
- Metabolic syndrome intervention
- Waist circumference reduction 3.8cm over 26 weeks
- No dedicated metabolic syndrome trials
- Preliminary data: 4.2cm waist reduction + 18% fasting insulin improvement at 12 weeks
- Blend shows promise for visceral adiposity + insulin resistance dual targeting; needs RCT validation
- Growth hormone deficiency replacement
- Off-label; not indicated (tesamorelin is GHRH analogue, not GH replacement)
- Studied as GH secretagogue in deficient adults; less effective than rhGH
- Combination may approach rhGH efficacy in mild deficiency while preserving endogenous regulation
- Reserve for research contexts where maintaining pituitary feedback is critical; not equivalent to pharmaceutical GH